Please assess the completion status of the following clinical trial:

Trial Title: TMQLB Versus TPVB for Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 17\~80 years of age;~* American Society of Anesthesiologists physical status I-III;~* undergoing laparoscopic nephrectomy.~Exclusion Criteria:~* have a known allergy to the anesthetics being used;~* infection at injection site~* coagulopathy or history of anticoagulants use~* chronic analgesics consumption or history of substance abuse~* inability to properly describe postoperative pain or recovery to investigators (e.g., language barrier, neuropsychiatric disorder).

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TMQLB group 1 (Type: EXPERIMENTAL): 0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
- TMQLB group 2 (Type: EXPERIMENTAL): 0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
- TPVB group (Type: ACTIVE_COMPARATOR): 0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.

Based on this trial design, predict the completion outcome and termination type (if applicable).